Active ingredientSarizotan DiHClCat. No. P-S017-001CAS 177976-12-4Family · Pharmaceutical analytical standards
Sarizotan
An investigational compound, a serotonin 5-HT1A receptor agonist and D2 receptor antagonist: it was studied for levodopa-induced dyskinesia in Parkinson's disease and then for breathing problems in Rett syndrome, and its development ended in 2020 without approval. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?In mouse models of Rett syndrome it cut apnoea by about 75 to 80% and corrected irregular breathing, making up for the brain serotonin deficit also seen in people with this syndrome.
Go to the active ingredient →Active ingredientSarizotan DiHClCat. No. P-S017-001CAS 177976-12-4
NitrosamineN-Nitroso SarizotanCat. No. P-S017-002
ImpuritySarizotan Impurity 1Cat. No. P-S017-003CAS 177976-33-9
Impurity5-(4-Fluorophenyl)-3-pyridinemethanolCat. No. P-S017-004CAS 222551-22-6
Impurityent-Sarizotan DiHClCat. No. P-S017-005CAS 177976-13-5
ImpuritySarizotan Impurity 2Cat. No. P-S017-006CAS 404337-71-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.